Showing 4561-4570 of 9406 results for "".
- New Data Show Efficacy of Topical 0.1% Stabilized Bioactive Retinol for Photoaginghttps://practicaldermatology.com/news/analysis-data-shows-efficacy-topical-01-stabilized-bioactive-retinol-photoaging/2462643/A recent integrated analysis published in the Journal of Drugs in Dermatology showed the efficacy and tolerability of topical 0.1% stabilized bioactive retinol in countering the signs of photoaging. "Advances in formulation science have allowed the production of stabilized bioact
- Analysis Highlights Factors Affecting Long-term Antibiotic Prescriptions for Acnehttps://practicaldermatology.com/news/analysis-highlights-factors-affecting-long-term-antibiotic-prescriptions-acne/2462633/A new analysis provided insight into the thinking of dermatologists prescribing antibiotics for treating acne. The research team set out to identify factors influencing prolonged oral antibiotic prescriptions for acne treatment by dermatologists, despite guidelines recommending limitation
- Study Validates Thermal Imaging, ALT-70 Model for Distinguishing Cellulitis from Pseudocellulitishttps://practicaldermatology.com/news/study-validates-thermal-imaging-alt-70-model-distinguishing-cellulitis-pseudocellulitis/2462541/A new diagnostic validation study in JAMA Dermatology has shed light on the potential of surface thermal imaging and the ALT-70 (asymmetry, leukocytosis, tachycardia, and age ≥70 years) prediction model in differentiating cellulitis from pseudocellulitis. "Cellulitis is misdiagno
- Deucravacitinib Improves Patient-Reported Outcomes for Psoriatic Arthritishttps://practicaldermatology.com/news/deucravacitinib-improves-patient-reported-outcomes-psoriatic-arthritis/2462540/Deucravacitinib, a TYK-2 inhibitor, was linked with significant improvements in patient-reported outcomes (PROs) in patients with active psoriatic arthritis (PsA), according to results from a phase 2 trial. To assess the effects of deucravacitinib in this patient population, the study aut
- Study: Pembrolizumab Shows Efficacy in Japanese Patients with Advanced Melanomahttps://practicaldermatology.com/news/study-pembrolizumab-shows-efficacy-japanese-patients-advanced-melanoma/2462539/A recent analysis of the phase 1b KEYNOTE-041 trial indicated effectiveness and tolerability of pembrolizumab in Japanese patients with advanced melanoma. Researchers conducted the study over a 12-month period. The study evaluated pembrolizumab's long-term efficacy and safety in individua
- Gene Variants May Drive Persistent Lesions in Darier Diseasehttps://practicaldermatology.com/news/gene-variants-may-drive-persistent-lesions-darier-disease/2462509/Persistent lesions in patients with Darier disease were associated with second-hit variants in the ATP2A2 gene, according to data from a new case series of 9 patients. In a study published in JAMA Dermatology, Lihi Atzmony, MD, of Rabin Medical Center, Petach Tikva, Israel, and c
- LEO Foundation Plans to Double Philanthropic Grants for Skin Diseaseshttps://practicaldermatology.com/news/leo-foundation-plans-double-philanthropic-grants-skin-diseases/2462483/Reporting a successful year in 2023, the LEO Foundation has announced its goals and aspirations out to 2030, including the awarding of a prestigious 5 million Danish kroner prize to a distinguished researcher in Denmark contributing to skin research. The Foundation plans to double its phi
- Probiotics Top List of Acne Supplement Ingredientshttps://practicaldermatology.com/news/probiotics-top-list-acne-supplement-ingredients/2462477/The most popular dietary supplements for acne contain probiotics, diindolylmethane, vitamin A, vitamin B complex, and zinc, according to a review of 13 supplements. Although surveys have shown that many acne patients opt for dietary supplements as adjunctive treatments, these products are
- American Acne and Rosacea Society (AARS) Releases Response to FDA Citizen's Petition from Valisurehttps://practicaldermatology.com/news/aars-releases-response-to-citizens-petition/2462445/The American Acne and Rosacea Society (AARS) has issued a public response to a recent report from Valisure showing common acne prod
- Galderma Prices IPO; Will Start Trading on the Swiss Stock Exchange Todayhttps://practicaldermatology.com/news/galderma-prices-ipo-will-start-trading-on-the-swiss-stock-exchange-today/2462444/Dermatology leader Galderma Group announced the pricing of its initial public offering at CHF 53 ($59) per share in Switzerland. The shares will be listed and start trading under the ticker symbol “GALD” on the SIX Swiss Exchange, on March 22, 2024. At the recent A